Name (Synonyms) | Correlation | |
---|---|---|
drug87 | Anti-SARS-CoV2 Serology Wiki | 0.32 |
drug1524 | bidirectional oxygenation mouthpiece Wiki | 0.32 |
drug6 | 0.9%NaCl Wiki | 0.32 |
drug1043 | Plaquenil 200Mg Tablet Wiki | 0.32 |
drug405 | Data collection up to 1 year Wiki | 0.32 |
drug761 | Lopinavir/ritonavir 400 mg/100 mg Wiki | 0.32 |
drug606 | Hydroxychloroquine Pre-Exposure Prophylaxis Wiki | 0.32 |
drug144 | BCG Vaccine Wiki | 0.18 |
drug591 | Hydroxychloroquine Wiki | 0.07 |
drug1035 | Placebo oral tablet Wiki | 0.06 |
drug1016 | Placebo Wiki | 0.05 |
Name (Synonyms) | Correlation | |
---|---|---|
D007246 | Infertility NIH | 0.32 |
D012170 | Retinal Vein Occlusion NIH | 0.32 |
D005157 | Facial Pain NIH | 0.32 |
D008268 | Macular Degeneration NIH | 0.32 |
D008269 | Macular Edema NIH | 0.32 |
D007153 | Immunologic Deficiency Syndromes NIH | 0.18 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.11 |
D004630 | Emergencies NIH | 0.11 |
D018352 | Coronavirus Infections NIH | 0.09 |
D007239 | Infection NIH | 0.08 |
D003141 | Communicable Diseases NIH | 0.06 |
D055371 | Acute Lung Injury NIH | 0.04 |
D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.04 |
D012128 | Respiratory Distress Syndrome, Adult NIH | 0.03 |
D011014 | Pneumonia NIH | 0.02 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0000789 | Infertility HPO | 0.32 |
HP:0011505 | Cystoid macular edema HPO | 0.32 |
HP:0012636 | Retinal vein occlusion HPO | 0.32 |
HP:0002721 | Immunodeficiency HPO | 0.18 |
HP:0002090 | Pneumonia HPO | 0.02 |
There are 10 clinical trials
Descriptive prospective study to investigate the prevalence of COVID 19 during ambulant screening
Description: Prevalence of fever, cough, anorexia, fatigue, diarrhea, vomiting, dyspnee, sore throat and sputum
Measure: Prevalence of symptoms Time: at the ambulant screeningDescription: Prevalence of positive COVID 19 tests in patients planned for surgery, treatment or investigation in the hospital
Measure: Prevalence of positive Sars CoV-2 PCR Time: at the ambulant screeningDescription: Prevalence of positive radiological findings in CT scans of the lungs of planned for surgery, treatment or investigation in the hospital
Measure: Prevalence of positive radiological findings Time: at the ambulant screeningDescription: Prediction of symptoms of COVID 19, based on evaluated baseline questionnaire
Measure: Prediction of symptoms Time: 2 weeks after surgery or treatmentDescription: Prediction of symptoms of COVID 19, based on radiological findings of CT scans
Measure: Prediction of symptoms Time: 2 weeks after surgery or treatmentDescription: Prediction of symptoms of COVID 19, based on COVID 19 PCR results
Measure: Prediction of symptoms Time: 2 weeks after surgery or treatmentThe outbreak linked to SARS-CoV-2 infection was declared a Public Health Emergency of International Concern on 30 January 2020. In all of the emergency Departments, a major reorganization was necessary, notably with the creation of a specific channel for COVID-19 suspect patients. Thus, all caregivers involved must adapt day by day to new places of exercise, new protocols,...The major influx of patients, the precautions to be taken, the specifics of the pathology and its management have profoundly changed daily practice. This exogenous hospital tension impacts all caregivers and more particularly their resilience capacities. Resilience is defined as an ability to recover from or adjust easily to misfortune or change. The Resi-CoV study aims to assess the level of resilience of caregivers of different specialties and trades in the context of covid-19.
Description: CD-RISC-25 : Connor-Davidson Resilience Scale - 25. This scale contain 25 questions each range from 1 to 5. The total is 100 points which means a very high level of resilience.
Measure: compare the level of resilience between physicians and caregivers of different specialties and in different workplaces according to the covid-19 epidemic. Time: 14 days"For 12 years, the odontology service of the Pitié-Salpêtrière hospital group (GHPS) has been responsible for day and night dental emergency care. Several surveys have been conducted in order to analyze the sociological characteristics of the patients and the typology of the acts performed. These studies indicate that pain is the main reason for consultations, cited by 60 to 80% of patients. So far, very few studies have been done in the context of emergencies. Very recently, a study was undertaken on the satisfaction of patients consulting the odontological emergencies of the GHPS, during a thesis work. This study, carried out in collaboration with the URC Pitié Salpêtrière, under analysis, relates to the satisfaction of patients consulting the odontological emergencies of the GHPS during the day and week, Monday to Friday, excluding night and week emergencies -end (WE). An additional study (URGDENT-NW) aiming at completing this study by focusing on patients consulting the emergency room at night and during the weekend is also in progress. The COVID19 Crisis changed the organization and the venue of patients at the emergency dental service. Therefore this project, based on the same protocol as URGENT and URGDENT-WE, aims at evaluating the Odontology Emergency Reception Service (SAUO) during the COVID 19 epidemy. It will be carried out in the form of a survey whose objective is to assess: on the one hand, the effectiveness of the care provided in this emergency functional unit, and on the other hand the satisfaction of the patients after their passage to the emergency room ."
Description: "Self report measure of pain on the numeric scale 24h after the visit "
Measure: Pain score evolution measured by a 0-10 numeric scale (NS) where 0 is no pain and 10 the worst pain imaginable Time: Day 1Description: the pain is measured with the numeric scale
Measure: Pain scores evolution 3 days and 7 days after first visit measured by a numeric scale where 0 is no pain and 10 the worst pain imaginable Time: Day 3 and Day 7Description: Perception of welcoming, waiting time will be measured with a 0-10 numeric scale
Measure: welcoming quality from hospital staff Time: Day 1Description: The patient anxiety will be measured by numeric scale at Day 0, Day 1, Day 3, Day 7
Measure: anxiety score Time: Day 0, Day 1, Day 3, Day 7Description: The perception is measured just after care with a 0-10 numeric scale
Measure: perception of the technical quality of the emergency treatment Time: Day 1This original study will assess the impact of the coronavirus health crisis on the management of patients undergoing medical treatment for cancer, in particularly on the modification of the hospital organization. It will also provide a record of the progress of patients who will have been treated during the epidemic period and infected by the virus. We will also assess the psychological impact of the pandemic in patients but also in caregivers
Description: Proportion of patients with modification of the treatments administered
Measure: To assess the impact of the COVID-19 pandemic on the modifications of treatments administered in hospital (day units) to patients with cancer or malignant hemopathy Time: up to 6 monthsDescription: Proportion of patients with change in the rate of treatment administration
Measure: To assess the impact of the COVID-19 pandemic on the change in the rate of treatment administration in hospital (day units) to patients with cancer or malignant hemopathy Time: up to 6 monthsDescription: Proportion of patients with change in the number of cures administered
Measure: To assess the impact of the COVID-19 pandemic on the number of cures administeredin hospital (day units) to patients with cancer or malignant hemopathy Time: up to 6 monthsDescription: Proportion of patients with change of modality of administration (home administration to replace day hospital administration, teleconsultation uses)
Measure: To assess the impact of the COVID-19 pandemic on change of modality of administration in hospital (day units) to patients with cancer or malignant hemopathy Time: up to 6 monthsDescription: Score of questionnaires of Perceived Stress Scale [0-40 points]
Measure: Evaluate the perceived stress on cancer patients treated in unit day of hospital Time: up to 6 monthsDescription: Score of questionnaires of Impact of Event Scale-Revised [0-88 points]
Measure: Evaluate the post-traumatic stress on cancer patients treated in unit day of hospital Time: up to 6 monthsDescription: Score of questionnaires of sleep disorders (ISI scale, 0-28 points)
Measure: Evaluate the sleep disorders on cancer patients treated in unit day of hospital Time: up to 6 monthsDescription: Score of questionnaires of quality of life (FACT-G scale)
Measure: Evaluate the quality of life on cancer patients treated in unit day of hospital Time: up to 6 monthsDescription: Score of questionnaires of cognitive complaints (Fact-Cog scales; 0-148 points)
Measure: Evaluate the cognitive complaints on cancer patients treated in unit day of hospital Time: up to 6 monthsDescription: Score of questionnaires of Perceived Stress Scale [0-40 points]
Measure: Evaluate the perceived stress on caregivers (perceived stress, post-traumatic stress, burnout, feeling of personal effectiveness) Time: up to 3 monthsDescription: Score of questionnaires of Impact of Event Scale-Revised [0-88 points]
Measure: Evaluate the post-traumatic stress on caregivers (perceived stress, post-traumatic stress, burnout, feeling of personal effectiveness) Time: up to 3 monthsDescription: Score of questionnaires of burnout ((Maslach Burn Out Inventory scale, 0-132 points)
Measure: Evaluate the burnout on caregivers (perceived stress, post-traumatic stress, burnout, feeling of personal effectiveness) Time: up to 3 monthsDescription: Score of questionnaires of feeling of personal effectiveness (0-30 points)
Measure: Evaluate the feeling of personal effectiveness on caregivers (perceived stress, post-traumatic stress, burnout, feeling of personal effectiveness) Time: up to 3 monthsA weekly questionnaire is sent to patients and parents of patients who are vulnerable for infections. Possible symptoms of COVID19 are asked for and use of healthcare services and testing for COVID19. Weekly reports are being send to the national institutions to update advice given to this group.
Description: To describe frequency of cough, fever, diarrhoea, shortness of breath, sore throat, blocked nose, red eyes, headache, joint pain, muscle pain, fatigue, chills, nausea, vomiting, diarrhoea over a year
Measure: To describe COVID19 infection in children/adults who are vulnerable for infection in an outpatients setting Time: 1 yearDescription: Patient/parent reported positive tests for COVID19
Measure: Number of children/adults tested positive for COVID19 Time: 1 yearDescription: Patient/parent reported admissions in hospital because of COVID19
Measure: Number of children/adults admitted in hospital because of COVID19 Time: 1 yearDescription: Patient/parent reported effect of COVID19 on daily activities
Measure: To assess the impact of COVID19 infection on the daily activities of immunosuppressed adults and children Time: 1 yearIt has been suggested that ibuprofen might be associated with more severe cases of coronavirus infections, based on the observation that severe COVID cases had been exposed to ibuprofen, resulting in a warning by the French authorities. This was attributed to: 1. a suggestion that ibuprofen might upregulate ACE-2 thereby increasing the entrance of COVID-19 into the cells, 2. an analogy with bacterial soft-tissue infections where more severe infections on NSAIDs are attributed to an immune-depressive action of NSAIDs, or to belated treatment because of initial symptom suppression, 3. fever is a natural response to viral infection, and reduces virus activity: antipyretic activity might reduce natural defenses against viruses. However fever reduction in critically ill patients had no effect on survival. However, these assertions are unclear: upregulation of ACEII would increase the risk of infection, not necessarily its severity, and would only apply to the use of NSAIDs before the infection, i.e. chronic exposure. It would be irrelevant to the infection once the patients are infected, i.e., to symptomatic treatment of COVID-19 infection. Anti-inflammatory effect masking the early symptoms of bacterial infections resulting in later antibiotic or other treatment is not applicable: there is no treatment of the virus that might be affected by masking symptoms. Antipyretic effect increasing the risk or the severity of infection would apply equally to all antipyretic agents including paracetamol, which share the same mechanism of action for fever reduction. EMA remains prudent about this assertion In addition, excess reliance on paracetamol while discouraging the use of ibuprofen might increase the risk of hepatic injury from paracetamol overdose. Paracetamol is the prime drug associated with liver injury and transplantation, in voluntary and inadvertent overdose or even at normal doses. This might be increased by COVID-related liver function alterations. It is therefore proposed to conduct a case-control study in a cohort of patients admitted to hospital in France with COVID-19 infection.
Description: Describe medications including ibuprofen used prior to admission associated with worse infection in COVID-19 patients in France. Thanks to a questionnaire created for the study, with 5 questions on existing pathology, drugs administrated symptom onset and when, hospitalisation. Each questions have a multiple choice.
Measure: Describe medications used prior to admission associated with worse infection in COVID-19 patients in France. Time: At inclusion dayDescription: Quantify medications including ibuprofen used prior to admission associated with worse infection in COVID-19 patients in France. Thanks to a questionnaire created for the study, with 5 questions: existing pathology, drugs administrated symptoms onset and when, hospitalisation. Each questions have a multiple choice.
Measure: Quantify medications used prior to admission associated with worse infection in COVID-19 patients in France. Time: At inclusion dayDescription: Describe patient characteristics thanks to the same questionnaire.
Measure: Describe other patient characteristics with worse infection in COVID-19 patients in France. Time: At inclusion dayDescription: Quantify patient characteristics thanks to the same questionnaire.
Measure: Quantify other patient characteristics with worse infection in COVID-19 patients in France. Time: At inclusion dayEmerging in China in December 2019, Covid-19, whose pathogen is SARS-Cov-2, was declared a global pandemic in March 2020. The clinical presentation is highly variable, ranging from asymptomatic forms to acute respiratory distress and even death. Transmission occurs through droplets, with a R0 of approximately 3. Rapidly, population protection measures were put in place by governments, including the confinement of all persons whose functions were not considered essential and the closure of educational institutions. Health care institutions are places at risk of Covid-19 transmission and hospital staff are particularly exposed, either through direct contact with patients, contact with exposed persons or through the environment. In order to protect personnel, hygiene measures were immediately recalled and reinforced. This study is aimed at evaluating the incidence rate of anti-SARS-Cov2 seroconversion over 2 months among hospital staff, without any supposed anti-Covid treatment 19.
Description: Change of Anti-SARS-Cov2 serological status between Day 0 and Day 60, measured in blood sample.
Measure: Anti-SARS-Cov2 seroconversion between Day 0 and Day 60. Time: From Day 0 to Day 60Description: Change of Anti-SARS-Cov2 serological status between Day 0 and Day 30, measured in blood sample.
Measure: Anti-SARS-Cov2 seroconversion between Day 0 and Day 30. Time: From Day 0 to Day 30Description: Change of Anti-SARS-Cov2 serological status between Day 30 and Day 60, measured in blood sample.
Measure: Anti-SARS-Cov2 seroconversion between Day 30 and Day 60. Time: From Day 30 to Day 60Description: Anti-SARS-Cov2 seroprevalence measured in blood sample collected at Day 0.
Measure: Anti-SARS-Cov2 seroprevalence at Day 0. Time: Day 0Description: Correlation between seroconversion (measured in blood sample) at Day 60 and sex
Measure: Correlation between seroconversion and socio-demographic factors - sex Time: Day 60Description: Correlation between seroconversion (measured in blood sample) at Day 60 and age
Measure: Correlation between seroconversion and socio-demographic factors - age Time: Day 60Description: Correlation between seroconversion (measured in blood sample) at Day 60 and job type (nurse, physician, etc.)
Measure: Correlation between seroconversion and professional factors - job type Time: Day 60Description: Correlation between seroconversion (measured in blood sample) at Day 60 and personal protective equipment type
Measure: Correlation between seroconversion and professional factors - personal protective equipment type Time: Day 60Description: Correlation between seroconversion (measured in blood sample) at Day 60 and contact with infected individuals
Measure: Correlation between seroconversion and non-professional factors - contact with infected individuals Time: Day 60Description: Correlation between seroconversion (measured in blood sample) at Day 60 and wearing of professional equipment
Measure: Correlation between seroconversion and non-professional factors - wearing of professional equipment Time: Day 60Description: Correlation between seroconversion (measured in blood sample) at Day 60 and respect of barrier gestures
Measure: Correlation between seroconversion and non-professional factors - respect of barrier gestures Time: Day 60In patients treated for exudative age-related macular degeneration (AMD), diabetes, retinal venous occlusion (OVR), or other conditions causing macular edema, treatments with anti-angiogenic intravitreal injections (IVT) are widely used both for their anti-angiogenic action. Patients often have injections for many years, sometimes monthly or every 2 months. The discontinuation of treatment with repeated injections of anti-angiogenic agents, linked to the COVID-19 coronavirus pandemic will potentially impact the visual acuity, the ophthalmological state and the quality of life of the patients concerned, therefore it is relevant to analyze the consequences the breakdown of usual care in this population.
Description: Change from baseline (last visual acuity before confinement) and visual acuity 6 months after resumption of follow-up
Measure: Change of visual acuity in patients treated with repeated IVT anti-angiogens during the COVID-19 epidemic Time: Baseline (Before confinement) and 6 months after resumption of follow-upThe COVID-19 pandemic brought new challenges to our nationwide healthcare system, with rapid escalation of the number of affected individuals over a handful of weeks. From March 13, a first set of measures was taken to minimise the spread of the virus, which largely impacted societal and economical daily life. A view days later, on March 17, the country was put in "lockdown" and all non-urgent medical treatments were cancelled or postponed. As recommended by the major scientific fertility societies, all non-ivf fertility treatments were discontinued abruptly, whereas started ivf stimulations were continued until oocyte aspiration, where after a freeze-all strategy was applied. There is little information available for women aiming for pregnancy or embarking on assisted conception. Given the modelling of the pandemic, including the time to peak and subsequent tail, considerable delays in conception to substantially attenuate risk may be required, which will inevitably impact patients wellbeing and overall success rates. A questionnaire was developed to explore patients perspectives on different aspects of their fertility treatment during the COVID-19 pandemic. The questionnaire contains the following sections: - demographic variables; - questions regarding the fertility history of the respondent; - questions regarding the impact of fertility treatment cancellation / postponing fertility treatment during COVID-19 on their life, psychological wellbeing and relationship; - questions regarding continuing medical treatment on their own, or seeking treatment elsewhere; - questions regarding the satisfaction of measures taken by their fertility center regarding the COVID-19 pandemic; - questions regarding expectations of further treatments, with focus on safety issues related to the COVID-19 pandemic. Eligible patients will be selected electronically from our database and digital agenda. After selection, patients will be contacted via email to participate. Two reminders will be send in case the questionnaire is not filled out: a first reminder after one week, a second reminder after two weeks.
The lockdown of the French population is a health measure put in place in response to the pandemic linked to a new coronavirus, SARS-CoV-2 (Covid-19). After a health campaign to recommend hygienic "barrier gestures" and social distancing, the decision to confine the population at the national level was decided by the executive from Monday 16 March to Monday 11 May 2020. The national confinement implies the restriction of movement to the strict necessary, outings near the home and the closure of schools and communities. These decisions have led to an unprecedented state of stress for the entire French population, the consequences of which are unknown in the short, medium or long term. The objectives of this study are to evaluate the psychological impact of the confinement on adolescents with or without chronic disease and also the difficulties and fears engendered by deconfinement .
Description: Scale 0-21
Measure: Anxiety score from the Generalized Anxiety Disorder 7 (GAD-7) questionnaire Time: At inclusionDescription: Scale 0-60
Measure: Depression score from the Adolescent Depression Rating Scale (ADRS) questionnaire Time: At inclusionDescription: 8 items that are scored on a four-point scale and 3 sub scales: intrusion (4 items); avoidance (4 items) and arousal (5 items)
Measure: Post traumatic score questionnaire: Children's Revised Impact of Events Scales -CRIES13 Time: At inclusionDescription: a question on the quality and quantity of sleep will be asked to the teenager on a questionnaire
Measure: Presence or absence of difficulty in falling asleep, sleeping Time: At inclusionDescription: a question on the presence or absence of feeding difficulty will be asked to the teenager on a questionnaire
Measure: Presence or absence of feeding difficulty Time: At inclusionDescription: a question on the presence or absence of difficulty performing physical activity will be asked to the teenager on a questionnaire
Measure: Presence or absence of difficulty performing physical activity Time: At inclusionDescription: a question on the presence or absence of toxic consomption will be asked to the teenager on a questionnaire
Measure: Presence or absence of toxic consomption (drug, acohol) during the lockdown Time: At inclusionDescription: A question on the presence or absence of difficulties with social interactions will be asked to the teenager on a questionnaire
Measure: Presence or absence of difficulties with social interactions Time: At inclusionDescription: Presence or absence of difficulties with familial interactions
Measure: Presence or absence of difficulties with familial interactions Time: At inclusion